Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:1800 DRFALK (1800 373 255) Email: admin@drfalkpharma.com.au

  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
HCP Portal
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
Contact:
Phone:
1800 DRFALK (1800 373 255)
Email:
admin@drfalkpharma.com.au
  • Homepage
  • Search

Search results

53 results

  • NEWSROOM
    Dosing of the First United States Patient
    ...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
  • NEWSROOM
    In memory of our founder
    100 years ago today, Dr. Dr. Herbert Falk was born
  • NEWSROOM
    FDA clearance of IND application for naronapride
    ...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
  • NEWSROOM
    Corum – Place To Share
    Read about yesterday's groundbreaking ceremony for the building in which we will be working in as of 2026.
  • NEWSROOM
    Following the footsteps of our founder
    Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
  • NEWSROOM
    Positive results from pivotal phase 3 trial on norucholic acid in PSC
    The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
  • NEWSROOM
    World EoE Day 2025
    Help to raise awareness on May 22, 2025!
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma Australia

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. 

  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
  • Crohn’s Disease
  • Eosinophilic Oesophagitis
  • Primary Biliary Cholangitis
  • Ulcerative colitis
© 2026 Dr. Falk Pharma Australia Pty Ltd
  • Terms & conditions of use
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are leaving the website of Dr. Falk Pharma in Australia.

We are not liable for the accuracy of any content published on third party websites – such as the one you are about to be forwarded to.